48.78 0.00 (0.00%)
After hours: 4:53PM EDT
|Bid||48.00 x 100|
|Ask||50.50 x 300|
|Day's Range||48.61 - 50.49|
|52 Week Range||45.31 - 71.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Seattle-area’s largest biotech already has a footprint of about 500,000 square feet, which includes seven office buildings in Bothell, a manufacturing facility in North Creek and a Seattle office.
The biotech sector was in focus last week with Protagonist's stock plunging on news of discontinuation of a phase IIb study and Verona Pharma stock surging on positive top-line data from COPD study among others.
“This marks the first time in four decades and 10 different attempts to replace one of the most toxic drugs ... for late-stage classical Hodgkin while increasing long-term survival,” founder and CEO Clay Siegall said.
Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.
Seattle Genetics' (SGEN) cancer drug, Adcetris, gets FDA approval to include fifth indication, frontline treatment of advanced classical Hodgkin lymphoma, in its label.
U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients, making it the first new treatment in over 40 years. The widely expected approval opens up a key market for Seattle Genetics, which expects the drug to bring in $1 billion in sales within the next few years. "We're 100 percent launch-ready," Chief Executive Clay Siegall said in an interview ahead of the decision.
Seattle Genetics Inc. has appointed Alpna Seth to its board of directors, expanding the board to nine people including two women. Seth’s more than 20 years of experience in health care and biotechnology will help Seattle Genetics continue to build out its growing pipeline of cancer drugs, which includes four applications of its flagship drug Adcetris. “Seattle Genetics is on the cusp of a significant inflection point in its transition into a global, multi-product oncology company,” Seth said in a news release.
Alpna Seth's appointment expands the Seattle biotech's board to nine people including two women. Seth is chief operating officer at San Francisco-based Vir Biotechnology and previously was a senior vice president at Cambridge, Mass.-based Biogen.
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Seattle Genetics Inc (NASDAQ:SGEN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
The Bothell, Washington-based company said it had a loss of 41 cents per share. The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research ...
Seattle Genetics (SGEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Intercept, Seattle Genetics and Corcept rose above the froth Thursday — popping on key drug, merger and earnings news.